Banks are seeing significant returns, with some outperforming the market indices in 2016. With the market currently in consolidation and President-Elect Trump close to beginning his term, investors are on the sidelines waiting for clearer indicators of what is to come in 2017 as well as during Trump’s remaining time in his term. The question remains whether the banking sector has been curtailing the overall market or contributing mostly to its key performance.
One factor remains to be a constant thorn in finding growth value stocks: all indices are coming off near highs and with continued consolidation. Whether the market will continue to move higher or finally meet its resistance is up in the air and anybody’s guess is as good as mine. If we are looking for investments that can provide value as well as dividends, we still have to worry about market risk. Regardless of an individual bank doing supremely well, the stock will begin to fade with its benchmark index. Th e current market risk is problematic, and I have previously expressed this concern in other articles. A portfolio investor can reduce total risk, but the chances of a pullback are high which hinders the investor’s ability to act on good value opportunities.
Hot Performing Stocks To Own For 2017: Amira Nature Foods Ltd(ANFI)
- [By Roberto Pedone]
Another earnings short-squeeze prospect is packaged specialty rice and other food products distributor Amira Nature Foods (ANFI), which is set to release numbers on next Monday after the market close. Wall Street analysts, on average, expect Amira Nature Foods to report revenue of $132.37 million on earnings of 32 cents per share.
The current short interest as a percentage of the float for Amira Nature Foods is extremely high at 26.6%. That means that out of 17.70 million shares in the tradable float, 4.72 million shares are sold short by the bears. The bears have also been increasing their bets from the last reporting period by 8.2%, or by 356,000 shares. If the bears get caught pressing their bets into a bullish quarter, then shares of ANFI could easily rip sharply higher post-earnings as the shorts move fast to cover some of their trades.
From a technical perspective, ANFI is currently trending above its 200-day moving average and just below its 50-day moving average, which is neutral trendwise. This stock just recently bounced higher off some near-term support at $15.25 a share. That bounce is starting to push shares of ANFI within range of triggering a near-term breakout trade post-earnings.
If you’re bullish on ANFI, then I would wait until after its report and look for long-biased trades if this stock manages to break out above some near-term overhead resistance levels at $17 to $17.98 a share and then above more resistance at $18.52 a share with high volume. Look for volume on that move that registers near or above its three-month average action of 174,102 shares. If that breakout develops post-earnings, then ANFI will set up to re-test or possibly take out its next major overhead resistance levels at $19.86 to $20.29 a share, or even its 52-week high at $25 a share.
I would simply avoid ANFI or look for short-biased trades if after earnings it fails to trigger that breakout and then drops back below some key near-term supp
Hot Performing Stocks To Own For 2017: Akorn, Inc.(AKRX)
- [By Wayne Duggan]
Akorn, Inc. (NASDAQ: AKRX) shares are up 18.2 percent on Friday after Bloomberg reported Frensius is considering a buyout bid for Akorn.
The news came just hours after Benzinga alerted its pro subscribers to an unusually large Akorn call purchase on the options market.
- [By Alex McGuire]
As a service to our readers, the following list provides the 10 top pharmaceutical stocks to watch this month (May 2017), including the biggest gainers from April…
Pharmaceutical Stock Current Share Price April 2017 Gain Cleveland BioLabs Inc. (Nasdaq: CBLI) $3.62 +120.6% Nexvet Biopharma Plc. (Nasdaq: NVET) $6.61 +69.7% Motif Bio Plc. (Nasdaq ADR: MTFB) $10.10 +68.2% Axovant Sciences Ltd. (NYSE: AXON) $24.43 +62.3% Cyclacel Pharmaceuticals Inc. (Nasdaq: CYCC) $5.49 +46.7% Conatus Pharmaceuticals Inc. (Nasdaq: CNAT) $8.67 +44.9% Akebia Therapeutics Inc. (Nasdaq: AKBA) $13.07 +43.3% Akorn Inc. (Nasdaq: AKRX) $33.28 +38.9% Rockwell Medical Inc. (Nasdaq: RMTI) $8.78 +37.4% Akari Therapeutics Plc. (Nasdaq ADR: AKTX) $15.02 +35.4%
The best-performing pharma stock of the month – Cleveland BioLabs Inc. – surged 120.6% to $3.53 a share by April 28. That crushed both the Nasdaq Biotech Index’s 1.5% gain and the Dow Jones’ 1.3% rise over the same period.
- [By Ben Levisohn]
Shares of Endo International (ENDP) have tumbled 40% today after it said profits would fall well short of analyst expectations thanks, in part, to plunging generic drug prices. Leerink’s Jason Gerberry and team look for specialty pharmaceutical companies that have similar business models–and find Akorn (AKRX), Perrigo (PRGO), and Teva Pharmaceutical Industries (TEVA). They explain:
- [By Dan Caplinger]
Despite a lack of conviction in the market at large, some stocks posted sharp gains on Friday, and Diana Shipping (NYSE:DSX), Akorn (NASDAQ:AKRX), and Granite Construction (NYSE:GVA) were among the best performers on the day. Below, we’ll look more closely at these stocks to tell you why they did so well.
Hot Performing Stocks To Own For 2017: Dow Treasuries(DV)
- [By Peter Graham]
A long term performance chart of Apollo Education Group along with peersITT Educational Services, Inc (NYSE: ESI) and DeVry Education Group Inc (NYSE: DV) reflect the headwinds from the Obama administration: